Login to Your Account



Alkermes lucky threes open door for Cerecor

By Randy Osborne
Staff Writer

Friday, October 21, 2016

Cerecor Inc.'s CMO, Ronald Marcus, acknowledging that upbeat phase III data from Alkermes plc in major depressive disorder MDD whetted appetites for his firm's pair of earlier-stage candidates, said tweaks in trial design can "dramatically improve your probability of success."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription